Key facts
- This page summarizes Benzion Abraham Friedman's Form 4 filing for Cell Source, Inc. (CLCS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jul 2021, 12:52.
Benzion Abraham Friedman - 30 Jun 2021 Form 4 Insider Report for Cell Source, Inc. (CLCS)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- CLCS
- Reported as of
- 30 Jun 2021
- Net transaction value
- +$14,580
- SEC form
- 4
- Accepted by SEC
- 07 Jul 2021, 12:52:28 UTC
- Prior SEC filing
- 10 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Benzion Friedman
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Benzion Abraham Friedman filed Form 4 for Cell Source, Inc. (CLCS) on 07 Jul 2021.
Change
- Previous filing in this sequence was filed on 10 Jun 2021.
- Current net transaction value: +$14,580.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLCS
transaction
Common Stock
Other
- Transaction value
- $14,580
- Shares
- +19,440
- Change %
- +0.44%
- Price
- $0.7500
- Shares after
- 4,408,184
- Date
- 30 Jun 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Issued as payment-in-kind dividend on Series A Convertible Preferred Stock.
Footnote F2
Owned by a company wholly owned by the wife of the reporting person.